Systemic Lupus Erythematosus Stem Cell Therapy Development

Systemic lupus erythematosus (SLE), a common autoimmune condition that affects women of childbearing age and results in multi-organ insufficiency, is a classic autoimmune disease. Infection is the main killer in this illness. SLE is fairly specific and has no known treatment. CD BioSciences has launched a development service for systemic lupus erythematosus stem cell therapies, dedicated to advancing the treatment of this disease.

Overview of Systemic Lupus Erythematosus

Clinical trials of stem cell therapy for SLE are still ongoing. Therefore, further clarification of the pathogenesis of the disease is needed. Type I interferon upregulates related genes and mediates critical antiviral responses. Many patients with SLE and other autoimmune diseases exhibit dysregulated type I interferon signaling, and the degree of this dysregulation is correlated with the severity of the disease. This makes type I interferon an appealing therapeutic target.

• Interferons are a Complex Family of Cytokines
  Based on sequence homology, interferons are cytokines with pleiotropic functions in immune regulation that can be divided into three families (type I, II, or III). Interferon [IFN]- is a member of the type II interferon family, and IFN-1-4 is a member of the type III interferon family. The largest interferon family is type I, which has 12 additional subgroups of IFN-like proteins in humans and consists of five classes (IFN-, IFN-, IFN-, and IFN-).
• Dysregulation of Type I Interferon Signaling Leads to the Development of SLE
  Systemic lupus erythematosus (SLE) can be triggered by chronic or dysregulated activation of the type I interferon pathway, despite the fact that the transient induction of type I interferon genes in response to viral stimuli is essential for host immunity. Autoimmune complex accumulation can lead to both localized and systemic inflammation.

Type I interferons and immune complex formation contributes to organ damage in the cycle of SLE pathophysiology. (Madhu Ramaswamy. et al. 2021)

• Advances in Type I Interferon-targeted Therapy
  Interferon-targeted therapies are currently being developed in clinical settings. For the treatment of patients with SLE, myositis, or LN as of 2021, four direct type I interferon-targeting therapies have been created and have shown varying clinical efficacy.

Advances in Stem Cell Therapy for Systemic Lupus Erythematosus

Hematopoietic and mesenchymal stem cells have made tremendous progress in the treatment of severe SLE in recent decades, but several challenges remain in their clinical application. After autologous HSCT, Th2 cell cytokine-like IL-4 reduced while Th1 cell cytokine-like IFN- g rose. Induction of interferon regulatory factor7 (IRF7) and phosphorylation of IRF3 were correlated with disease flare after HSCT. Therefore, further research on molecular mechanisms can accelerate the application of stem cell therapy in SLE.

Our Services

CD BioSciences offers systemic lupus erythematosus stem cell therapy development services. With our professional research team and mature experimental system, we are able to provide one-stop R&D services to our customers. Based on our professional laboratory team, we can contribute to the development of stem cell therapy for systemic lupus erythematosus.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Madhu Ramaswamy. et al. (2021). The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Int J Mol Sci. 22(20):11286.